FDA accepts new drug review for extended release Aricept

Share this content:
Eisai's Aricept tablets have been accepted for review by the Food and Drug Administration, according to the company. The medication is indicated for the treatment of moderate to severe Alzheimer's disease. This new higher dose formulation allows for gradual release of the drug.